PMID: 75439Feb 25, 1978Paper

Maintenance treatment of recurrent peptic ulcer by cimetidine

Lancet
G Bodemar, A Walan

Abstract

68 patients with chronic peptic ulcer took part in a double-blind trial in which 32 received the histamine H2-receptor antagonist cimetidine, (400 mg twice daily) and 36 received a placebo, for a year. 6 of those on cimetidine had an endoscopically proven recurrent ulcer within a mean of 7 months, while 30 of those on placebo had one after a mean of 4 months (P less than 0.0005). 1 patient on cimetidine had two recurrences compared with 12 patients on placebo (P less than 0.0005). No patient in the cimetidine group had complications compared to 4 patients in the placebo group, 2 of whom had melaena and haematemesis and 2 melaena alone (P less than 0.05). 15 patients on placebo and 1 on cimetidine were referred for surgery during the trial because of symptoms from their recurrent ulcers. Day and night ulcer pain and antacid consumption were significantly less, and general wellbeing better, in cimetidine group. The only probable side-effect of cimetidine was reversible drug-induced liver damage of hypersensitivity type in 1 patient.

Citations

Jan 1, 1981·European Journal of Clinical Pharmacology·A DanielssonL Steen
Apr 17, 1979·European Journal of Clinical Pharmacology·R LarssonB Norlander
Nov 1, 1984·Digestive Diseases and Sciences·F PalmasG Verme
Jan 1, 1986·Digestive Diseases and Sciences·S GustavssonO Nyrén
Nov 1, 1988·Journal of General Internal Medicine·R S LaneJ D Goodson
Jul 1, 1980·Irish Journal of Medical Science·J M WaltersC F McCarthy
Aug 1, 1978·Irish Journal of Medical Science·I E EustaceJ P McMullin
Sep 27, 2005·Digestive Diseases and Sciences·Helge L WaldumGunnar Qvigstad
Mar 1, 1981·Social Science & Medicine. Medical Economics·A J Culyer, A K Maynard
Jan 1, 1991·Social Science & Medicine·B Jönsson, P Carlsson
May 1, 1992·Social Science & Medicine·A J BarskyG L Klerman
Sep 10, 1999·Psychosomatics·A J BarskyM H Liang
Jan 5, 1980·Lancet·Y J Drabu, P J Sanderson
Mar 29, 1980·Lancet·W S RuddellM J Hill
Jun 1, 1981·Klinichna khirurhiia·A A Shalimov, V F Saenko
May 11, 1978·The New England Journal of Medicine·J S Fordtran
Nov 2, 1978·The New England Journal of Medicine·W Finkelstein, K J Isselbacher
Apr 27, 1989·The New England Journal of Medicine·G M Van DeventerJ H Walsh
Jun 3, 1978·British Medical Journal
Jan 20, 1979·British Medical Journal·J H BaronJ R Bennett
Jul 1, 1978·British Medical Journal·P C Sharpe, C Wastell
Jul 8, 1978·British Medical Journal·C G Clark, J H Wyllie
Aug 5, 1978·British Medical Journal·W L BurlandR J Horton
Nov 11, 1978·British Medical Journal·A G MorganA V Simmons
Jul 1, 1992·Postgraduate Medical Journal·H J O'Connor
Aug 9, 2003·Expert Opinion on Drug Safety·Helge L WaldumArne K Sandvik
Mar 1, 1987·The American Journal of Medicine·R I Horwitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.